Objective: The objective of this study was to assess the risk of cancer in patients with RA treated with biologic and targeted synthetic DMARDs (b/tsDMARDs).
Methods: We analysed the 2000-2023 data for RA patients from the BIOBADASER III registry, a multicentre national registry of patients treated with b/tsDMARDs. Patients with a history of cancer were excluded. Incidence rates (IRs) were analysed, and adjusted Cox regression models were used to estimate hazard ratios (HRs) for all cancers excluding non-melanoma skin cancer (NMSC), as well as for NMSC. Treatment with a TNF inhibitor (TNFi) served as the reference for comparison.
Results: Among 4635 of the BIOBADASER III registry patients with RA (mean age 55.5 years; 79% female; median follow-up 3.6 years), 187 incident cancers were identified. For all cancers excluding NMSC, the adjusted HRs (95% CI) compared with TNFi were: 1.2 (0.8-1.6) for IL6i, 0.9 (0.5-1.4) for CD20i, 1.2 (0.8-1.8) for JAKi and 1.1 (0.8-1.6) for CTLA4-A. For NMSC, the adjusted HRs (95% CI) were 0.6 (0.2-1.5) for IL6i, 0.6 (0.2-1.8) for CD20i, 0.7 (0.2-2) for JAKi, and 1.1 (0.5-2.6) for CTLA4-A. No increased cancer risk was observed when adjusting for cardiovascular risk or treatment line, for either cancer type.
Conclusion: In this large, real-world cohort of RA patients, we found no increased cancer risk associated with any bDMARDs or tsDMARDs compared with TNFi.
Keywords: DMARDs; biologics; cancer; epidemiology; registries; rheumatoid arthritis; targeted therapies.
© The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.